Coronavirus company news summary - 3a-diagnostics identifies biosensor candidates for oral screening - Leaf Space to launch satellite-driven telemedicine tool for monitoring - Verdict Medical Devices
Join Our Newsletter - Get important industry news and analysis sent to your inbox – sign up to our e-Newsletter here
X

Coronavirus company news summary – 3a-diagnostics identifies biosensor candidates for oral screening – Leaf Space to launch satellite-driven telemedicine tool for monitoring

29 Jul 2021

3a-diagnostics has identified biosensor candidates that can be used for affordable and easy oral screening and quick detection of Covid-19 in real-time. Activated by saliva, the candidates are based on the oral dissolvable delivery platform of XPhyto Therapeutics, which agreed earlier this month to acquire 3a-diagnostics. Apart from Covid-19, the biosensor candidates can be used to detect other infectious diseases in at-home and point-of-care settings.

Qorvo has reported that its Qorvo Omnia SARS-CoV-2 Antigen Test platform was validated in two independent studies performed by the Atlanta’s Center for Microsystems Engineered Point-of-Care Technologies (ACME-POCT) and funded by the National Institutes of Health (NIH). The adult and pediatric studies demonstrated the low SARS-CoV-2 limit of detection as well as high specificity and sensitivity of the test when compared with the Roche cobas 6800 and Hologic Panther RT-PCR systems.

Leaf Space is set to launch a new telemedicine solution via satellite for monitoring of Covid-19 patients at home. The solution is part of the company’s CARES project, which is funded by the European Space Agency. A suite of medical devices linked to a smartphone, CARES captures the vitals of a patient by leveraging medical software and remotely sends those vitals to a database that doctors can directly access from a web browser. The remote platform enables monitoring and care for Covid-19 patients, particularly those who are recovering from the disease.